ArticleProceedings of the National Academy of Sciences of the United States of America2014

Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers.

Yong Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.